J45
Conditions
Interventions
Group 1: Patients with Eosinophilic asthma (sputum eosinophils => 3%):
Included patients will be assessed twice, once at baseline and the second time three month later (Follow-up). The assessments inc
Sponsors
Koordinationszentrum für klinische Studien
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: • Age: 18–65 years • Recorded diagnosis (by a pulmonologist) of Asthma • Signed informed consent
Exclusion criteria
Exclusion criteria: • Active smoking • Ex-smokers that stopped smoking less than 12 months prior to inclusion • COPD (according to GOLD guidelines; http://www.goldcopd.org) • Treatment with very high doses of ICS (>800 µg/die budesonide equivalent) or systemic steroids at the time of inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the predictive value (at visit 1) of the VOC (volatile organic compound) profile analysis regarding sputum eosinophilia (= 3%), as assessed by AUC (area unter the curve) of the ROC (Receiver Operator characteristics) curve of the linear discriminant (electronic nose) | — |
Secondary
| Measure | Time frame |
|---|---|
| - to analyse the predictive value of the VOC (volatile organic compound) profile analysis (at visit 1) for the clinical course (as measured by the change in ACQ-7) within three months | — |
Countries
Germany
Contacts
Public ContactUrsula Boas
Universitätsklinikum Giessen und Marburg Innere Medizin, Pneumologie
Outcome results
None listed